{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:26:51Z","timestamp":1787819211719,"version":"build-2784847793"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Human immunodeficiency virus (HIV) infection is a risk factor for pulmonary hypertension (PH). Chronic hepatitis C virus (HCV) infection may have unique or synergistic effects on the pulmonary vasculature, but the prevalence and risk factors for PH in HIV-HCV coinfected persons are not known.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To define the prevalence of echocardiographic PH in a cohort of patients with HIV-HCV coinfection, to compare this estimate with the reported prevalence of PH among those with HIV infection alone, and to identify potential risk factors for PH in coinfected individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective study of HIV-HCV coinfected patients followed at our institution from 2003 to 2012 with evidence of HCV infection (positive HCV antibody, measurable HCV ribonucleic acid viral load, and\/or genotype) within 6 months of transthoracic echocardiogram. PH was defined by an estimated pulmonary artery systolic pressure (PASP) of greater than or equal to 40 mm Hg or more than moderate right ventricular dysfunction. We excluded those diagnosed with cirrhosis, left ventricular ejection fraction less than 50%, or more than moderate aortic or mitral valve disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>Sixty-eight patients were included, and 43 had adequate estimates of PASP. The median (interquartile range) age was 52 (48\u201357) years, and 45 (67%) were men. Eight (19%) had PH, and three (7%) had more than moderate right ventricular dysfunction. After age and sex adjustment, interferon (IFN)-based HCV treatment was associated with higher PASP (\u03b2, 6.00 mm Hg; 95% confidence interval, 0.09\u201311.90; P = 0.047) and with the risk of PH (odds ratio, 5.65; 95% confidence interval, 1.07\u201329.93; P = 0.042). These associations persisted after adjustment for comorbidities but were attenuated by adjustment for duration of HCV diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The prevalence of echocardiographic PH may be higher in HIV-HCV coinfected individuals than in those with HIV monoinfection. IFN-based HCV treatment and time since HCV diagnosis were associated with the development of PH as assessed by echocardiography. Further studies are needed to examine HIV-HCV coinfection, HCV treatment, and duration of infection as possible causes of pulmonary vascular disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.201405-225oc","type":"journal-article","created":{"date-parts":[[2014,11,6]],"date-time":"2014-11-06T16:20:58Z","timestamp":1415290858000},"page":"1553-1559","source":"Crossref","is-referenced-by-count":20,"title":["Risk of Echocardiographic Pulmonary Hypertension in Individuals with Human Immunodeficiency Virus\u2013Hepatitis C Virus Coinfection"],"prefix":"10.1093","volume":"11","author":[{"given":"Rohit B.","family":"Sangal","sequence":"first","affiliation":[{"name":"Alpert Medical School of Brown University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn E.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Alpert Medical School of Brown University"},{"name":"Division of Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fizza","family":"Gillani","sequence":"additional","affiliation":[{"name":"Alpert Medical School of Brown University"},{"name":"Division of Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena","family":"Poppas","sequence":"additional","affiliation":[{"name":"Alpert Medical School of Brown University"},{"name":"Cardiovascular Institute, Lifespan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Klinger","sequence":"additional","affiliation":[{"name":"Alpert Medical School of Brown University"},{"name":"Division of Pulmonary, Sleep, and Critical Care Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey E.","family":"Ventetuolo","sequence":"additional","affiliation":[{"name":"Alpert Medical School of Brown University"},{"name":"Division of Pulmonary, Sleep, and Critical Care Medicine, and"},{"name":"Department of Health Services, Policy, and Practice, Alpert Medical School of Brown University, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,12,1]]},"reference":[{"key":"2026012303482122500_bib1","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1378\/chest.118.4.1133","article-title":"HIV-related pulmonary hypertension: analytic review of 131 cases","volume":"118","author":"Mehta","year":"2000","journal-title":"Chest"},{"key":"2026012303482122500_bib2","doi-asserted-by":"crossref","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","article-title":"Updated clinical classification of pulmonary hypertension","volume":"62","author":"Simonneau","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026012303482122500_bib3","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1164\/ajrccm.155.3.9117037","article-title":"JollerJemelka HI, Jenni R, Russi EW, Hirschel B, L\u00fcthy R. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study","volume":"155","author":"Opravil","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303482122500_bib4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1164\/rccm.200704-541OC","article-title":"Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era","volume":"177","author":"Sitbon","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303482122500_bib5","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1378\/chest.100.5.1268","article-title":"Primary pulmonary hypertension in HIV infection","volume":"100","author":"Speich","year":"1991","journal-title":"Chest"},{"key":"2026012303482122500_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1586\/ers.11.17","article-title":"Viral infection and pulmonary hypertension: is there an association?","volume":"5","author":"Cool","year":"2011","journal-title":"Expert Rev Respir Med"},{"key":"2026012303482122500_bib7","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1182\/blood.V82.9.2774.2774","article-title":"Exogenous tat protein activates human endothelial cells","volume":"82","author":"Hofman","year":"1993","journal-title":"Blood"},{"key":"2026012303482122500_bib8","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1164\/ajrccm.151.5.7735624","article-title":"Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension","volume":"151","author":"Humbert","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303482122500_bib9","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1128\/JVI.78.6.3099-3109.2004","article-title":"Extracellular Nef protein targets CD4+ T cells for apoptosis by interacting with CXCR4 surface receptors","volume":"78","author":"James","year":"2004","journal-title":"J Virol"},{"key":"2026012303482122500_bib10","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1513\/pats.201006-046WR","article-title":"Pathogenesis of HIV-associated pulmonary hypertension: potential role of HIV-1 Nef","volume":"8","author":"Almodovar","year":"2011","journal-title":"Proc Am Thorac Soc"},{"key":"2026012303482122500_bib11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1164\/rccm.200601-005OC","article-title":"HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques","volume":"174","author":"Marecki","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303482122500_bib12","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1089\/aid.2011.0021","article-title":"Human immunodeficiency virus nef signature sequences are associated with pulmonary hypertension","volume":"28","author":"Almodovar","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2026012303482122500_bib13","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1093\/cid\/cis367","article-title":"HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms","volume":"55","author":"Taylor","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026012303482122500_bib14","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1164\/rccm.201110-1909OC","article-title":"Enhanced pulmonary arteriopathy in simian immunodeficiency virus-infected macaques exposed to morphine","volume":"185","author":"Spikes","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012303482122500_bib15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews","volume":"378","author":"Nelson","year":"2011","journal-title":"Lancet"},{"key":"2026012303482122500_bib16","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1093\/cid\/cit326","article-title":"Management of hepatitis C virus\/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy","volume":"57","author":"Taylor","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2026012303482122500_bib17","doi-asserted-by":"crossref","first-page":"e46779","DOI":"10.1371\/journal.pone.0046779","article-title":"Effect of different interferon\u03b12 preparations on IP10 and ET-1 release from human lung cells","volume":"7","author":"Badiger","year":"2012","journal-title":"PLoS One"},{"key":"2026012303482122500_bib18","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s10620-010-1220-7","article-title":"Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C","volume":"55","author":"Dhillon","year":"2010","journal-title":"Dig Dis Sci"},{"key":"2026012303482122500_bib19","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3851\/IMP2349","article-title":"A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin","volume":"17","author":"Reiberger","year":"2012","journal-title":"Antivir Ther"},{"key":"2026012303482122500_bib20","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"2026012303482122500_bib21","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.echo.2010.05.010","article-title":"Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography","volume":"23","author":"Rudski","year":"2010","journal-title":"J Am Soc Echocardiogr"},{"key":"2026012303482122500_bib22","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: a report from the American Society of Echocardiography\u2019s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"key":"2026012303482122500_bib23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/ejechocard\/jep007","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography","volume":"10","author":"Nagueh","year":"2009","journal-title":"Eur J Echocardiogr"},{"key":"2026012303482122500_bib24","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/cid\/ciq066","article-title":"High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy","volume":"52","author":"Mondy","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2026012303482122500_bib25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijcard.2003.04.069","article-title":"Hepatitis C and the heart: to beat or not to beat","volume":"96","author":"Kcomt","year":"2004","journal-title":"Int J Cardiol"},{"key":"2026012303482122500_bib26","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/hep.22275","article-title":"Clinical risk factors for portopulmonary hypertension","volume":"48","author":"Kawut","year":"2008","journal-title":"Hepatology"},{"key":"2026012303482122500_bib27","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1378\/chest.128.4.2882","article-title":"Hepatitis C virus and the lung: implications for therapy","volume":"128","author":"Moorman","year":"2005","journal-title":"Chest"},{"key":"2026012303482122500_bib28","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1096\/fj.03-0153fje","article-title":"Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1alpha","volume":"18","author":"Moon","year":"2004","journal-title":"FASEB J"},{"key":"2026012303482122500_bib29","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/QAI.0b013e3181b67527","article-title":"Trends in hepatitis C virus infection among patients in the HIV Outpatient Study, 1996-2007","volume":"53","author":"Spradling","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026012303482122500_bib30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000335064","article-title":"Sildenafil therapy for interferon-\u03b2-1a-induced pulmonary arterial hypertension: a case report","volume":"120","author":"Caravita","year":"2011","journal-title":"Cardiology"},{"key":"2026012303482122500_bib31","author":"Savale","year":"2014"},{"key":"2026012303482122500_bib32","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1007\/s002770100298","article-title":"Pulmonary artery hypertension during interferon-alpha therapy for chronic myelogenous leukemia","volume":"80","author":"Fruehauf","year":"2001","journal-title":"Ann Hematol"},{"key":"2026012303482122500_bib33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1476-7120-3-26","article-title":"Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report","volume":"3","author":"Jochmann","year":"2005","journal-title":"Cardiovasc Ultrasound"},{"key":"2026012303482122500_bib34","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1111\/jvh.12020","article-title":"Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin","volume":"20","author":"Foster","year":"2013","journal-title":"J Viral Hepat"},{"key":"2026012303482122500_bib35","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/jvh.12105","article-title":"Evidence that pulmonary vascular pathology explains the decline in lung function associated with interferon \u03b1 based therapies for chronic hepatitis C virus","volume":"20","author":"George","year":"2013","journal-title":"J Viral Hepat"},{"key":"2026012303482122500_bib36","doi-asserted-by":"crossref","first-page":"24297","DOI":"10.1074\/jbc.M109.032524","article-title":"Synergistic induction of endothelin-1 by tumor necrosis factor alpha and interferon gamma is due to enhanced NF-kappaB binding and histone acetylation at specific kappaB sites","volume":"284","author":"Wort","year":"2009","journal-title":"J Biol Chem"},{"key":"2026012303482122500_bib37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pharmthera.2012.03.006","article-title":"Pharmacology and therapeutic potential of interferons","volume":"135","author":"George","year":"2012","journal-title":"Pharmacol Ther"},{"key":"2026012303482122500_bib38","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0014-2999(99)00107-7","article-title":"Interferon-alpha elevates pulmonary blood pressure in sheep\u2014the role of thromboxane cascade","volume":"370","author":"Hanaoka","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"2026012303482122500_bib39","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","article-title":"ACCF\/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association","volume":"53","author":"McLaughlin","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026012303482122500_bib40","doi-asserted-by":"crossref","first-page":"D42","DOI":"10.1016\/j.jacc.2013.10.032","article-title":"Definitions and diagnosis of pulmonary hypertension","volume":"62","author":"Hoeper","year":"2013","journal-title":"J Am Coll Cardiol"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/11\/10\/1553\/66484191\/annalsats_11_10_1553.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/11\/10\/1553\/66484191\/annalsats_11_10_1553.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:48:33Z","timestamp":1769158113000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/11\/10\/1553\/8431827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,1]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,12,1]]},"published-print":{"date-parts":[[2014,12,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.201405-225oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,12]]},"published":{"date-parts":[[2014,12,1]]}}}